Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Inc. CYBN

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies London Healthcare Conference

Posted on November 11, 2021 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the Jefferies London Healthcare Conference. The event is slated to be held in a virtual … Continue reading →

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Posted on November 9, 2021 by MissionIR

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company  is … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Demonstrates Numerous Advantages over Oral Psilocybin for Treatment of Mental Health

Posted on November 8, 2021 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive CYB003 pre-clinical findings. According to the update, the findings demonstrate multiple advantages for Cybin’s newly developed novel deuterated psilocybin analog over oral … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Schedule I Manufacturing License from DEA

Posted on November 4, 2021 by MissionIR

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM), has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”). Granted for Cybin’s research lab located in the Boston area, the … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings

Posted on November 2, 2021 by MissionIR

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough … Continue reading →

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unveils Psychedelic Facilitator Training Program Based on Groundbreaking Psychotherapy Approach

Posted on October 28, 2021 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is launching its own psychedelic facilitator training program. Called EMBARK, the project is led by expert faculty and provides psychedelic clinical trial facilitators with fundamental training … Continue reading →

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study

Posted on October 26, 2021 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Posted on October 20, 2021 by MissionIR

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation The … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio

Posted on October 19, 2021 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to … Continue reading →

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio

Posted on October 12, 2021 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. … Continue reading →

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment